2024
Imaging chronic active lesions in multiple sclerosis: a consensus statement
Bagnato F, Sati P, Hemond C, Elliott C, Gauthier S, Harrison D, Mainero C, Oh J, Pitt D, Shinohara R, Smith S, Trapp B, Azevedo C, Calabresi P, Henry R, Laule C, Ontaneda D, Rooney W, Sicotte N, Reich D, Absinta M. Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain 2024, 147: 2913-2933. PMID: 38226694, PMCID: PMC11370808, DOI: 10.1093/brain/awae013.Peer-Reviewed Original ResearchChronic active lesionsMagnetic resonance imagingConsensus statementMultiple sclerosisActive lesionsManifestations of chronic inflammationParamagnetic rim lesionsMRI-definedNorth American ImagingRadiological definitionChronic inflammationRim lesionsClinical translationLesionsResonance imagingMRI sequencesIn vivoT1-wBrains of personsBiomarkers
2017
Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care
Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH, Gupta A, Tsiouris AJ, Kovanlikaya I, Chiang G, Weinsaft JW, Tanenbaum L, Chen W, Zhu W, Chang S, Lou M, Kopell BH, Kaplitt MG, Devos D, Hirai T, Huang X, Korogi Y, Shtilbans A, Jahng G, Pelletier D, Gauthier SA, Pitt D, Bush AI, Brittenham GM, Prince MR. Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. Journal Of Magnetic Resonance Imaging 2017, 46: 951-971. PMID: 28295954, PMCID: PMC5592126, DOI: 10.1002/jmri.25693.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingQuantitative susceptibility mappingPatient careGradient-echo magnetic resonance imagingEcho magnetic resonance imagingAbnormal oxygen consumptionContrast agent injectionNormal cellular biochemistryMRI diagnosisPathologic processesMRI protocolResonance imagingAgent injectionBone mineralizationSpatial biodistributionGradient echo sequencePathologic calcificationJ. MagnTechnical efficacyDiseaseClinical applicationOxygen consumptionClinical translationMRI practiceImaging practices
2016
Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping
Stüber C, Pitt D, Wang Y. Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping. International Journal Of Molecular Sciences 2016, 17: 100. PMID: 26784172, PMCID: PMC4730342, DOI: 10.3390/ijms17010100.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMagnetic resonance imagingBrain tissueQuantitative susceptibility mappingMS brain tissueAdvanced MRI methodsMS patientsChronic inflammationImmunohistochemical investigationBrain ironMyeloid cellsResonance imagingNon-invasive studyHistological studyRole of ironOxidative stressNoninvasive imagingSclerosisInflammationCellular distributionMRI methodsNeurodegenerationTissueImagingPatients
2013
Quantitative Susceptibility Mapping of Multiple Sclerosis Lesions at Various Ages
Chen W, Gauthier SA, Gupta A, Comunale J, Liu T, Wang S, Pei M, Pitt D, Wang Y. Quantitative Susceptibility Mapping of Multiple Sclerosis Lesions at Various Ages. Radiology 2013, 271: 183-92. PMID: 24475808, PMCID: PMC4263629, DOI: 10.1148/radiol.13130353.Peer-Reviewed Original ResearchConceptsNormal-appearing white matterMS lesionsMultiple sclerosis lesionsEnhanced lesionsQuantitative susceptibility mappingMR examinationsSclerosis lesionsConventional magnetic resonance imagingMagnetic resonance imagingT2-weighted imagesMS patientsPathophysiologic featuresCerebrospinal fluidOnline supplemental materialWhite matterLesionsQSM imagesResonance imagingPatientsMR imagingThree-dimensional gradient-echo sequenceGradient echo sequenceMonthsBonferroni correctionAgeLessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis Treated With Natalizumab
Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D. Lessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis Treated With Natalizumab. JAMA Neurology 2013, 70: 398-402. PMID: 23338729, DOI: 10.1001/jamaneurol.2013.1960.Peer-Reviewed Original ResearchConceptsProgressive multifocal leukoencephalopathyBrain magnetic resonance imagingMagnetic resonance imagingMultiple sclerosisResonance imagingMultifocal leukoencephalopathyPolymerase chain reaction testingFatal progressive multifocal leukoencephalopathyBenefits of natalizumabInfusions of natalizumabPML risk stratificationAntibody-positive patientsHigh-dose corticosteroidsCerebrospinal fluid studiesHigh clinical suspicionCerebrospinal fluid analysisBrain magnetic resonanceNegative test resultsPolymerase chain reaction resultsSubacute onsetBilateral blindnessClinical suspicionClinical vigilanceCortical demyelinationTherapy duration
2010
Imaging Cortical Lesions in Multiple Sclerosis With Ultra–High-Field Magnetic Resonance Imaging
Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, Rammohan K, Knopp MV, Schmalbrock P. Imaging Cortical Lesions in Multiple Sclerosis With Ultra–High-Field Magnetic Resonance Imaging. JAMA Neurology 2010, 67: 812-818. PMID: 20625086, DOI: 10.1001/archneurol.2010.148.Peer-Reviewed Original ResearchConceptsCortical lesion detectionCortical lesionsMultiple sclerosisLesion typeCortical multiple sclerosis lesionsBrain tissueCortical lesion typesMultiple sclerosis tissueAutopsied brain tissueInversion recoveryMagnetic resonance imagingMultiple sclerosis lesionsCorresponding histological sectionsLesion detectionMyelin basic proteinHypointense ringUndetected lesionsImmunohistochemical analysisSclerosis lesionsLesionsResonance imagingSensitivity of T2SclerosisMagnetic resonance imagesLesion visibility